Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Requires Expedited P&T Review For New Drugs In Six Protected Classes

Executive Summary

Part D drug plan pharmacy & therapeutics committees must make coverage decisions about new drugs or new indications within 90 days of their entry into the market in Medicare's six "all or substantially all" therapeutic categories, the Centers for Medicare & Medicaid Services states in its final formulary review 1guidelines for the 2007 contract year

You may also be interested in...



AHRQ Antidepressant Report May Put Pressure On CMS Formulary Guidelines

An Agency for Healthcare Research & Quality draft report finding no substantial efficacy difference among second-generation antidepressants could increase pressure on CMS' "all or substantially all" coverage policy for the class

AHRQ Antidepressant Report May Put Pressure On CMS Formulary Guidelines

An Agency for Healthcare Research & Quality draft report finding no substantial efficacy difference among second-generation antidepressants could increase pressure on CMS' "all or substantially all" coverage policy for the class

Part D Specialty Tier Should Be Reserved For Highest-Priced Drugs – BIO

Too many drugs will be subject to the maximum copay on Part D formularies if CMS allows plans to place all therapies with negotiated prices greater than $500 per month on the specialty tier, according to the Biotechnology Industry Organization

Related Content

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel